
|Videos|November 10, 2022
ENHANCE-2 Trial of Magrolimab plus Azacitidine in AML
Author(s)Hetty E. Carraway, MD, Eytan M. Stein, MD
Dr Stein explains clinical trial data on the use of magrolimab plus azacitidine for patients with TP53-mutated AML.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
3
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5




















